These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Failure of epoprostenol (prostacyclin, PGI2) to inhibit platelet aggregation and to prevent restenosis after coronary angioplasty: results of a randomised placebo controlled trial. Gershlick AH; Spriggins D; Davies SW; Syndercombe Court YD; Timmins J; Timmis AD; Rothman MT; Layton C; Balcon R Br Heart J; 1994 Jan; 71(1):7-15. PubMed ID: 8297699 [TBL] [Abstract][Full Text] [Related]
5. Effects of taprostene, a chemically stable prostacyclin analogue, in patients with ischaemic peripheral vascular disease: a placebo controlled double-blind trial. Virgolini I; Fitscha P; O'Grady J; Barth H; Sinzinger H Prostaglandins Leukot Essent Fatty Acids; 1989 Oct; 38(1):31-5. PubMed ID: 2514430 [TBL] [Abstract][Full Text] [Related]
6. Prostacyclin treatment of ischemic ulcers and rest pain in unreconstructible peripheral arterial occlusive disease. Cronenwett JL; Zelenock GB; Whitehouse WM; Lindenauer SM; Graham LM; Stanley JC Surgery; 1986 Aug; 100(2):369-75. PubMed ID: 3526609 [TBL] [Abstract][Full Text] [Related]
7. Failure to demonstrate beneficial effect of prostacyclin (PGI2) infusion on red blood cell deformability in patients with peripheral vascular disease: a possible role of the leukocytes. Parise P; Berrettini M; Grasselli S; de Cunto M; Nenci GG Angiology; 1992 Apr; 43(4):320-7. PubMed ID: 1558317 [TBL] [Abstract][Full Text] [Related]
8. Effect of glutathione infusion on leg arterial circulation, cutaneous microcirculation, and pain-free walking distance in patients with peripheral obstructive arterial disease: a randomized, double-blind, placebo-controlled trial. Arosio E; De Marchi S; Zannoni M; Prior M; Lechi A Mayo Clin Proc; 2002 Aug; 77(8):754-9. PubMed ID: 12173710 [TBL] [Abstract][Full Text] [Related]
9. Salvage of the severely ischaemic limb by intra-arterial prostacyclin (PGI2) infusion. A case report. Søreide O; Segadal L; Trippestad A; Engedal H Scand J Thorac Cardiovasc Surg; 1982; 16(1):71-3. PubMed ID: 7041251 [TBL] [Abstract][Full Text] [Related]
10. Trial of a novel prostacyclin analog, UT-15, in patients with severe intermittent claudication. Mohler ER; Klugherz B; Goldman R; Kimmel SE; Wade M; Sehgal CM Vasc Med; 2000; 5(4):231-7. PubMed ID: 11213235 [TBL] [Abstract][Full Text] [Related]
12. Prolonged infusion of prostacyclin in patients with advanced stages of peripheral vascular disease: a placebo-controlled cross-over study. Hossmann V; Auel H; Rücker W; Schrör K Klin Wochenschr; 1984 Dec; 62(23):1108-14. PubMed ID: 6394890 [TBL] [Abstract][Full Text] [Related]
13. [Prostacyclin and pentoxifylline in the treatment of patients with inoperable occlusions of the peripheral arteries of the lower extremities]. Maksimović ZV Srp Arh Celok Lek; 1999; 127(7-8):249-53. PubMed ID: 10624398 [TBL] [Abstract][Full Text] [Related]
14. The effect of ciprostene in patients with peripheral vascular disease (PVD) characterized by ischemic ulcers. The Ciprostene Study Group. J Clin Pharmacol; 1991 Jan; 31(1):81-7. PubMed ID: 2045533 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of intravenous infusion of prostacyclin (PGI2) or prostaglandin E1 (PGE1) in augmentation of skin flap blood flow and viability in the pig. Forrest CR; Pang CY; Zhong AG; Kreidstein ML Prostaglandins; 1991 Jun; 41(6):537-58. PubMed ID: 2052739 [TBL] [Abstract][Full Text] [Related]
17. Continuous intravenous dosing with ciprostene using a portable pump in ambulatory patients. Wolf DL; Metzler CM; Froeschke MO; Luderer JR J Clin Pharmacol; 1993 Feb; 33(2):150-3. PubMed ID: 8440764 [TBL] [Abstract][Full Text] [Related]
18. A preliminary double-blind cross-over trial of lipo-PGI2, a prostacyclin derivative incorporated in lipid microspheres, in cerebral infarction. Hoshi K; Mizushima Y Prostaglandins; 1990 Aug; 40(2):155-64. PubMed ID: 2217831 [TBL] [Abstract][Full Text] [Related]
19. [Comparison of the effectiveness of physical training with parenteral drug therapy in Fontaine stage IIb peripheral arterial occlusive disease]. Streminski JA; de la Haye R; Rettig K; Kuntz G Vasa; 1992; 21(4):392-402. PubMed ID: 1485475 [TBL] [Abstract][Full Text] [Related]
20. [Trial treatment of severe Raynaud's phenomenon with prostacyclin (PGI2)]. Cabane J; Boue F; Godeau P; Lecompte T; Charpentier MC; Samama M; Nebout T Rev Med Interne; 1985 Dec; 6(5):581-9. PubMed ID: 3914023 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]